ATE231884T1 - Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i - Google Patents

Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i

Info

Publication number
ATE231884T1
ATE231884T1 AT95915611T AT95915611T ATE231884T1 AT E231884 T1 ATE231884 T1 AT E231884T1 AT 95915611 T AT95915611 T AT 95915611T AT 95915611 T AT95915611 T AT 95915611T AT E231884 T1 ATE231884 T1 AT E231884T1
Authority
AT
Austria
Prior art keywords
peptides
activity
cytotoxic
regulation
mhc class
Prior art date
Application number
AT95915611T
Other languages
English (en)
Inventor
Carol Clayberger
Alan M Krensky
Peter Parham
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE231884T1 publication Critical patent/ATE231884T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95915611T 1994-04-05 1995-04-05 Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i ATE231884T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/222,851 US5723128A (en) 1987-01-30 1994-04-05 Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
PCT/US1995/004349 WO1995026979A1 (en) 1994-04-05 1995-04-05 Cytotoxic t-cell lymphocyte ('ctl') activity regulation by class i mhc peptides

Publications (1)

Publication Number Publication Date
ATE231884T1 true ATE231884T1 (de) 2003-02-15

Family

ID=22833972

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95915611T ATE231884T1 (de) 1994-04-05 1995-04-05 Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i

Country Status (8)

Country Link
US (1) US5723128A (de)
EP (1) EP0753005B1 (de)
JP (1) JPH10501791A (de)
AT (1) ATE231884T1 (de)
CA (1) CA2187193A1 (de)
DE (1) DE69529515T2 (de)
ES (1) ES2186717T3 (de)
WO (1) WO1995026979A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US6436903B1 (en) * 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
AU761717B2 (en) * 1997-04-11 2003-06-05 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
AU2003286611A1 (en) * 2002-10-24 2004-05-13 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
WO2006031226A1 (en) * 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
US20090023895A1 (en) * 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
US8324345B2 (en) 2006-10-12 2012-12-04 Nec Corporation HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same
EP2206726A1 (de) * 2009-01-08 2010-07-14 Universite Joseph Fourier Nichtinvasive Instrumente zum Nachweisen anfälliger atherosklerotischer Plaques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
ATE126237T1 (de) * 1987-01-30 1995-08-15 Univ Leland Stanford Junior Lymphocyteninhibierung durch hla-peptide.
WO1989007448A1 (en) * 1988-02-12 1989-08-24 Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
EP0459978B1 (de) * 1989-03-03 1997-07-16 The Regents Of The University Of California Klasse i-mhc-modulation von oberflächenrezeptoraktivität
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
CA2081582A1 (en) * 1991-11-05 1993-05-06 Teodorica Bugawan Methods and reagents for hla class i dna typing

Also Published As

Publication number Publication date
JPH10501791A (ja) 1998-02-17
ES2186717T3 (es) 2003-05-16
DE69529515T2 (de) 2003-06-12
CA2187193A1 (en) 1995-10-12
DE69529515D1 (de) 2003-03-06
WO1995026979A1 (en) 1995-10-12
EP0753005A4 (de) 1997-06-18
EP0753005A1 (de) 1997-01-15
EP0753005B1 (de) 2003-01-29
US5723128A (en) 1998-03-03

Similar Documents

Publication Publication Date Title
ES2150949T3 (es) Regulacion de la actividad de linfocitos con la ayuda de peptidos hla.
ATE231884T1 (de) Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69435171D1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
NZ335749A (en) Formulation in the form of a patch for transcutaneous immunization comprising an antigen and an adjuvant
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
GEP20022648B (en) Method for Inducing T Cell Tolerance to a Tissue or Organ Graft
NO974258L (no) IL-17-reseptor
DK549188A (da) Lymfocythaemmende hla-peptider
DE69329344T2 (de) Spezifische modulationen des immunsystems
NO943967D0 (no) Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider
MX9603431A (es) Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.
IT1235928B (it) Dispositivo di tenuta per cilindri rotanti come forni e simili
MX9703535A (es) Linfocitos t dirigidos.
KR890700659A (ko) 항원-특이적 t세포주의 생성방법 및 이의 치료적 용도
AU1086888A (en) Primary biliary cirrhosis autoantigen
NO930798L (no) Fremgangsmaate og middel mot tumorer
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
MY131097A (en) Pharmaceutical compositions comprising interleukin-2
IT8320622V0 (it) Dispositivo di serraggio perestremita' libere di cavi, funi e simili.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties